查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046265

失眠治療市場－全球產業規模、佔有率、趨勢、機會與預測：按類型、藥物、通路、地區和競爭格局分類，2021-2031年

Insomnia Treatment Market - Global Industry Size, Share, Trends, Opportunities and Forecast, Segmented By Type, By Drugs, By Distribution Channel By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球失眠治療市場預計將從 2025 年的 38.2 億美元大幅成長至 2031 年的 53.2 億美元，複合年成長率為 5.68%。

該市場涵蓋多種藥物和非藥物療法，旨在解決入睡困難和睡眠維持障礙。推動這一市場成長的主要因素包括壓力和焦慮加劇、老年人口不斷成長（老年人更容易出現睡眠週期紊亂）以及公眾對睡眠不足嚴重健康影響的認知不斷提高。例如，根據美國睡眠醫學會的報告，到2024年，將有12%的美國人被診斷出患有慢性失眠症，凸顯了需要有效治療的患者數量龐大。

市場概覽
預測期 2027-2031
市場規模：2025年 38.2億美元
市場規模：2031年 53.2億美元
複合年成長率：2026-2031年 5.68%
成長最快的細分市場 Zolpidem
最大的市場 北美洲

儘管市場成長前景樂觀，但仍面臨許多挑戰，主要與傳統藥物療法相關的安全性和依賴風險有關。長期使用鎮靜劑和安眠藥可能產生不良副作用，這是一項重大挑戰，可能會降低患者的治療依從性，並限制醫生的處方行為。此外，針對藥物安全性和有效性標準的嚴格監管審查仍然使新產品的核准極其困難，這可能會阻礙市場的快速擴張。

市場促進因素

全球慢性睡眠障礙盛行率的不斷上升是失眠治療市場的主要驅動力，也因此產生了對有效治療方法的巨大且迫切的需求。在現代生活方式中，工作與生活界線的模糊性日益加劇，導致睡眠障礙病例激增，因此全球範圍內都需要藥物治療和行為療法。這種日益成長的負擔並非空穴來風。發表於2025年8月《睡眠醫學評論》的一項系統性回顧估計，全球有8.52億成年人患有失眠症，凸顯了確診患者數量的龐大。同時，消費者的認知也發生了顯著轉變，睡眠如今被認為是整體健康的重要組成部分。正如SingleCare在2025年發布的報告顯示，全球80%的成年人希望改善睡眠，這顯示除了臨床患者之外，更廣泛的健康消費群體也擁有巨大的市場潛力。

此外，數位療法和睡眠追蹤領域的技術創新正在改變市場格局，為傳統鎮靜劑提供了已被證實有效的非藥物替代方案。處方箋數位療法 (PDT) 的應用日益普及，該療法透過軟體提供認知行為療法 (CBT-I) 來治療失眠，從而降低了長期藥物依賴帶來的安全隱患。近期監管和報銷系統的進步顯著提升了該領域的信譽度，這對於確保商業性可行性和患者可及性至關重要。正如 HealthcareBrew 在 2025 年 4 月報道的那樣，美國醫療保險和醫療補助服務中心 (CMS) 於 2025 年 1 月推出了一項新的計費代碼，使醫療服務提供者能夠就數位心理健康療法申請報銷。將數位干預措施整合到現有的支付系統中，正在推動醫生採用這些療法，也是數位睡眠健康領域收入穩定成長的關鍵驅動力。

市場挑戰

全球失眠治療市場擴張面臨的主要障礙在於傳統藥物療法固有的安全性問題和依賴風險。長期服用鎮靜劑和安眠藥會產生認知障礙、成癮風險和持續性日間嗜睡等副作用，這給市場帶來了巨大的阻力。這些安全隱患顯著降低了患者繼續治療的意願，也使得醫生不願將這些藥物作為維持治療方案，從而限制了製藥公司的潛在基本客群和穩定收入。

新的調查結果加劇了這項挑戰，也引起了監管機構和公眾的更多關注。 2025年，美國心臟協會報告稱，長期使用某些助眠藥物會使慢性失眠患者發生心臟衰竭的風險增加89%。這些證據凸顯了安全問題的嚴重性，並加深了人們對藥物療法的懷疑，同時迫使該行業適應更複雜和嚴格的監管環境，直接減緩了市場成長。

市場趨勢

一個值得關注的市場趨勢是朝向雙重Orexin受體拮抗劑（DORA）的轉變。這標誌著藥物研發從傳統的鎮靜催眠藥（通常抑制中樞神經系統）發展到更高級的藥物。與誘導全身鎮靜的Z類藥物不同，DORA能夠精準靶向並阻斷促進覺醒的神經肽，從而在抑制覺醒的同時維持自然的睡眠模式。這種作用機制降低了人們對藥物依賴性和認知障礙的擔憂，因此迅速被尋求長期維持治療的臨床醫生所接受。這一轉變的商業性成功體現在其主要產品的強勁表現上。根據Eisai發布的《2024會計年度財務業績報告》（2025年5月），其DORA治療藥物「Davigo」的銷售額達到538億日元，年增128.6%。

另一個重要趨勢是雇主贊助的睡眠健康計畫迅速普及，因為企業已經意識到睡眠健康與工作效率之間的關鍵連結。企業正逐步將睡眠管理解決方案納入員工福利，以減少「在崗主義」（即員工雖在崗但無法發揮全部潛能）並降低醫療保健成本。企業之所以進行這項投資，是因為有數據表明，未經治療的睡眠不足會造成巨大的經濟影響。例如，瑞思邁（ResMed）發布的第五屆年度全球睡眠調查（2025年2月）發現，在13個市場中，70%的員工在其職業生涯中至少請過一次病假，而這直接導致了企業加大對預防性睡眠干預措施的投入。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球失眠治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 失眠的類型（急性失眠、慢性失眠、入睡困難、睡眠維持障礙、兒童行為性失眠）
    • 依藥物分類（依佐匹克隆、雷美替胺、Zaleplon、Zolpidem、艾司唑侖等）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美失眠治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲失眠治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區失眠治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲失眠治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲失眠治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球失眠治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck & Co
  • Pfizer Inc.
  • Abbott Laboratories
  • Genentech Inc.
  • LGM Pharma
  • Sigma Aldrich Corp.
  • Sanofi SA
  • Takeda Pharmaceuticals Co. Ltd.
  • Eisai Ltd.
  • Idorsia Pharmaceuticals Apotex Corp

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17295

The global insomnia treatment market is projected to expand significantly, rising from USD 3.82 billion in 2025 to USD 5.32 billion by 2031, demonstrating a compound annual growth rate of 5.68%. This market encompasses various pharmacological and non-pharmacological treatments aimed at addressing difficulties in falling and staying asleep. Key factors driving this growth include the increasing rates of stress and anxiety, a growing elderly population prone to sleep cycle disturbances, and greater public awareness of the serious health consequences of insufficient sleep. In 2024, for example, 12% of Americans had a chronic insomnia diagnosis, as reported by the American Academy of Sleep Medicine, highlighting a considerable patient population in need of effective treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.82 Billion
Market Size 2031USD 5.32 Billion
CAGR 2026-20315.68%
Fastest Growing SegmentZolpidem
Largest MarketNorth America

Despite these positive growth projections, the market faces considerable obstacles primarily related to the safety and dependency risks linked with traditional drug therapies. The risk of adverse side effects from the prolonged use of sedative-hypnotics poses a major challenge, potentially discouraging patients from adhering to treatment and limiting prescriptions by doctors. Furthermore, stringent regulatory scrutiny concerning drug safety and efficacy standards continues to complicate the approval of new products, which could hinder the market's rapid expansion.

Market Driver

The increasing global prevalence of chronic sleep disorders is a primary driver fueling the insomnia treatment market, generating substantial and urgent demand for effective therapies. Contemporary lifestyles, which often blur the lines between professional and personal time, have led to a surge in sleep disturbances, requiring both medicinal and behavioral approaches worldwide. This growing burden is well-documented; a systematic review in Sleep Medicine Reviews (August 2025) estimated that 852 million adults globally suffer from insomnia disorder, highlighting a vast, diagnosed patient population. Concurrently, there is a strong shift in consumer perception, with sleep now recognized as a vital component of overall health; SingleCare reported in 2025 that 80% of adults globally aspire to improve their sleep, indicating extensive market potential beyond clinical patients to the broader wellness consumer.

Furthermore, technological innovations in digital therapeutics and sleep tracking are transforming the market by providing proven, non-pharmacological options to conventional sedatives. The industry is increasingly adopting prescription digital therapeutics (PDTs) that deliver cognitive behavioral therapy for insomnia (CBT-I) through software, thereby mitigating the safety concerns linked to prolonged drug dependency. This segment has gained significant credibility through recent regulatory and reimbursement advancements crucial for its commercial viability and patient accessibility. As reported by Healthcare Brew in April 2025, the Centers for Medicare and Medicaid Services (CMS) introduced new billing codes effective January 2025, enabling healthcare providers to claim reimbursement for digital mental health treatments. This integration of digital interventions into established payment systems is a crucial impetus, encouraging physician adoption and fostering consistent revenue growth in the digital sleep health sector.

Market Challenge

A significant obstacle impeding the expansion of the global insomnia treatment market stems from the safety profiles and dependency risks inherent in traditional pharmacotherapy. The market experiences considerable pushback due to adverse effects associated with long-term use of sedative-hypnotics, including cognitive impairment, the potential for addiction, and persistent daytime drowsiness. These safety issues substantially reduce patient willingness to continue treatment and make physicians reluctant to prescribe such medications for ongoing maintenance, consequently restricting the potential customer base and consistent revenue for drug companies.

This challenge is exacerbated by new research that heightens both regulatory and public examination. In 2025, the American Heart Association reported studies linking the extended use of specific sleep aids to an 89% increased risk of incident heart failure in chronic insomnia patients. Such evidence highlights the severity of the safety concern, reinforcing skepticism towards pharmaceutical interventions and compelling the industry to navigate a more intricate and stringent regulatory landscape, which directly slows market growth.

Market Trends

A notable market trend is the move towards Dual Orexin Receptor Antagonists (DORAs), which signifies an evolution beyond conventional sedative-hypnotics that generally suppress the central nervous system. In contrast to Z-drugs that induce general sedation, DORAs precisely target and block wake-promoting neuropeptides, thereby inhibiting wakefulness while maintaining natural sleep patterns. This mechanism alleviates worries about dependency and cognitive impairment, leading to swift adoption by clinicians seeking long-term maintenance therapies. The commercial success of this shift is clear from the strong performance of leading products; Eisai Co., Ltd.'s 'Consolidated Financial Report for Fiscal 2024' (May 2025) showed that revenue for its DORA treatment, Dayvigo, soared to ¥53.8 billion, representing a 128.6% increase year-on-year.

Another significant trend is the increasing proliferation of employer-sponsored sleep wellness programs, spurred by businesses recognizing the crucial link between sleep health and workforce productivity. Companies are progressively incorporating sleep management solutions into their employee benefit offerings to mitigate presenteeism and lower healthcare expenditures. This corporate investment is justified by data illustrating the financial impact of untreated sleep deprivation. For instance, ResMed's 'Fifth Annual Global Sleep Survey' (February 2025) revealed that 70% of employed individuals across 13 markets had taken a sick day specifically due to poor sleep at least once in their career, motivating businesses to fund preventative sleep interventions.

Key Market Players

  • Merck & Co
  • Pfizer Inc.
  • Abbott Laboratories
  • Genentech Inc.
  • LGM Pharma
  • Sigma Aldrich Corp.
  • Sanofi S.A
  • Takeda Pharmaceuticals Co. Ltd.
  • Eisai Ltd.
  • Idorsia Pharmaceuticals Apotex Corp

Report Scope

In this report, the Global Insomnia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Insomnia Treatment Market, By Type

  • Acute Insomnia Chronic Insomnia
  • Onset Insomnia
  • Maintenance Insomnia
  • Behavioral Insomnia of Childhood

Insomnia Treatment Market, By Drugs

  • Eszopiclone
  • Ramelteon
  • Zaleplon
  • Zolpidem
  • Estazolam
  • Others

Insomnia Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Insomnia Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Insomnia Treatment Market.

Available Customizations:

Global Insomnia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Insomnia Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Acute Insomnia Chronic Insomnia, Onset Insomnia, Maintenance Insomnia, Behavioral Insomnia of Childhood)
    • 5.2.2. By Drugs (Eszopiclone, Ramelteon, Zaleplon, Zolpidem, Estazolam, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Insomnia Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drugs
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Insomnia Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Drugs
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Insomnia Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drugs
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Insomnia Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drugs
        • 6.3.3.2.3. By Distribution Channel

7. Europe Insomnia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drugs
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Insomnia Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drugs
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Insomnia Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drugs
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Insomnia Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drugs
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Insomnia Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drugs
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Insomnia Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drugs
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Insomnia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drugs
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Insomnia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drugs
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Insomnia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drugs
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Insomnia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drugs
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Insomnia Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drugs
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Insomnia Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drugs
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Insomnia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drugs
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Insomnia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drugs
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Insomnia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drugs
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Insomnia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drugs
        • 9.3.3.2.3. By Distribution Channel

10. South America Insomnia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drugs
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Insomnia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drugs
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Insomnia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drugs
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Insomnia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drugs
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Insomnia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck & Co
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Abbott Laboratories
  • 15.4. Genentech Inc.
  • 15.5. LGM Pharma
  • 15.6. Sigma Aldrich Corp.
  • 15.7. Sanofi S.A
  • 15.8. Takeda Pharmaceuticals Co. Ltd.
  • 15.9. Eisai Ltd.
  • 15.10. Idorsia Pharmaceuticals Apotex Corp

16. Strategic Recommendations

17. About Us & Disclaimer